
Universe Pharmaceuticals Inc.
UPCNASDAQHealthcare● Active
$3.24
$-0.01(-0.31%)
Market Cap$1825159
P/E Ratio—
52W High$11
52W Low$2
Universe Pharmaceuticals Inc.(UPC)· 现金流量表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q(经 FMP 聚合)· 可在下方切换周期与 M/B/T 单位。
FMP · UPC · 截至 2026-06-15
财务报表
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-09 | 2024-09 | 2023-09 | 2022-09 | 2021-09 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($3.67M) | ($8.73M) | ($6.58M) | ($7.91M) | $11.32M |
| Depreciation & Amort. | $0.52M | $0.49M | $0.51M | $0.53M | $0.45M |
| Stock-Based Comp. | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Change in Working Capital | ($2.27M) | ($2.06M) | $5.67M | $6.60M | ($12.69M) |
| Net Cash from Operations | ($5.05M) | ($9.51M) | $1.12M | ($1.31M) | ($2.06M) |
| Investing Activities | |||||
| Capital Expenditure | ($0.35M) | ($0.36M) | ($0.04M) | ($0.09M) | ($13.53M) |
| Purchases of Investments | $0.00M | $0.00M | $0.00M | $0.00M | ($15.33M) |
| Sales of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $1.80M |
| Net Cash from Investing | ($0.34M) | ($0.36M) | ($0.04M) | ($3.91M) | ($27.06M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | ($5.27M) | $8.95M | ($1.39M) | $3.32M | $0.62M |
| Net Cash from Financing | $9.73M | $33.95M | ($1.39M) | $3.32M | $26.58M |
| Free Cash Flow | |||||
| Free Cash Flow | ($5.40M) | ($9.87M) | $1.08M | ($1.41M) | ($15.59M) |
| FCF Margin %(computed) | -30.23% | -42.87% | 3.33% | -3.50% | -32.49% |
数据来源:Financial Modeling Prep · 最后更新:2026-06-15 · USD · M
深入了解Universe Pharmaceuticals Inc.
关于Universe Pharmaceuticals Inc.(UPC)现金流量表
Universe Pharmaceuticals Inc. 2025财年经营活动现金流($0.01B),自由现金流($0.01B)(FCF利润率-30.23%),资本支出($0.00B)。
常见问题
UPC · 4 问Universe Pharmaceuticals Inc. 2025财年自由现金流($0.01B),同比up45.3%。
UPC free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-15